The construction of the world's most powerful solution-type medical isotope test reactor commenced on Tuesday in Southwest China's Sichuan Province, according to information obtained by the Global Times from the China National Nuclear Corporation (CNNC). This development aims to better address the diagnostic and treatment requirements of tens of millions of people in China.
After becoming operational, this reactor, constructed by the Nuclear Power Institute of China under CNNC, is projected to have an annual production capacity of 100,000 curies of molybdenum-99 and 20,000 curies of iodine-131. This will address the longstanding reliance on imports and the bottleneck issue concerning these two isotopes.
Furthermore, this development is expected to catalyze the downstream industry, generating an output value of more than 4 billion yuan ($0.56 billion), thereby significantly enhancing cancer diagnosis and treatment capabilities in China.
Medical isotopes are typical radioactive isotopes that have been successfully employed in the field of medicine. Carbon-14, a mainstream medical isotope, is utilized in breath tests to detect Helicobacter pylori during routine physical examinations.
Zhao Guang, the director of the medical isotope department at the Nuclear Power Institute of China, told the Global Times that dozens of medical isotopes, such as carbon-14, iodine-131, iodine-125, and strontium-89, are highly sought-after in the detection and treatment of major diseases. However, China has traditionally depended heavily on imports for its supply of medical isotopes.
A research report from the Nuclear Power Institute of China indicates that in recent years, China has depended on imports for more than 90 percent of medical isotopes produced through nuclear reactors, with a limited variety. Meanwhile, there is a gradual increase in domestic demand for medical isotopes.